Hinduja Global Solutions (HGS) Q4 24/25 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 24/25 earnings summary
2 Nov, 2026Executive summary
FY25 operating revenue was ₹4,404.2 crore and EBITDA ₹811.8 crore, at a 16.4% margin; Q4 revenue was ₹1,161.1 crore and EBITDA ₹279.2 crore, at a 21.5% margin.
FY25 PAT was ₹100.7 crore, including a ₹218.54 crore gain from discontinued healthcare operations; continuing operations recorded a ₹117.82 crore loss.
Market softness, political uncertainty and extended sales cycles weighed on performance; priorities include margin expansion and digital operations growth.
Financial highlights
Q4 FY25 operating revenue was ₹1,161.06 crore, up from ₹1,064.1 crore in Q3 and ₹1,098.7 crore in Q4 FY24.
Q4 total income was ₹1,297.7 crore; EBITDA was ₹279.2 crore and margin 21.5%, versus 19.0% in Q3 and 17.9% in Q4 FY24.
Q4 PBT was ₹103.45 crore and PAT was a ₹1.69 crore loss; tax expense was ₹105.1 crore, largely reflecting deferred tax.
FY25 revenue from operations was ₹4,404.18 crore vs ₹4,615.72 crore in FY24; EBITDA was ₹811.8 crore vs ₹828 crore, with margins of 16.4% vs 16.3%.
FY25 PAT was ₹100.72 crore vs ₹131.16 crore; total income was ₹4,958.76 crore vs ₹5,087.78 crore.
Outlook and guidance
H2 FY25 contracts are expected to contribute significant revenue growth in FY26; digital services are expected to rise as a share of revenue.
FY26 priorities include margin expansion, smaller and shorter projects, digital operations growth in North America, the UK and Australia, and offshore delivery.
Initial packaged AI solutions are planned for consumer and retail, BFSI, and TMT, with a dedicated product, delivery, R&D and go-to-market team.
Broadband plans include organic subscriber growth, upselling, underserved markets, higher CelerityX contract value and IPTV rollout to key cities in early Q2.
Latest events from Hinduja Global Solutions
- Q2 operating EBITDA rose 30% as cost discipline offset muted growth.HGS
Q2 23/24 - Q3 EBITDA surged and PBT turned positive amid digital growth and uncertain demand.HGS
Q3 23/24 - FY2024 operating EBITDA rose 45.8% as AI-led growth advanced amid unresolved tax-search exposure.HGS
Q4 23/24 - One-time costs pressured margins; healthcare-sale gain lifted PAT, with recovery expected from Q2.HGS
Q1 24/25 - UK and macro headwinds cut revenue as technology and AI initiatives advanced.HGS
Q2 24/25 - Q3 EBITDA margin reached 19% as AI-led growth advanced amid near-term revenue pressure.HGS
Q3 24/25 - Margin expansion and digital traction amid softer Q1 revenue.HGS
Q1 25/26 - FY26 EBITDA fell 20.1%; record wins and Project GANGA support growth prospects.HGS
Q4 25/26 - Revenue held broadly steady as continuing losses widened; client wins and Project GANGA advanced.HGS
Q1 26/27